TY - JOUR
T1 - Active Surveillance for Adverse Events Within 90 Days
T2 - The Standard for Reporting Surgical Outcomes After Pancreatectomy
AU - Schwarz, Lilian
AU - Bruno, Morgan
AU - Parker, Nathan H.
AU - Prakash, Laura
AU - Mise, Yoshihiro
AU - Lee, Jeffrey E.
AU - Vauthey, Jean Nicolas
AU - Aloia, Thomas A.
AU - Conrad, Claudius
AU - Fleming, Jason B.
AU - Katz, Matthew H.G.
N1 - Publisher Copyright:
© 2015, Society of Surgical Oncology.
PY - 2015/10/15
Y1 - 2015/10/15
N2 - Background: The rate of adverse events after pancreatectomy is widely reported as a measure of surgical quality. However, morbidity data are routinely acquired retrospectively and often are reported at 30 days. The authors hypothesized that morbidity after pancreatectomy is therefore underreported. They sought to compare rates of adverse events calculated at multiple time points after pancreatectomy. Methods: The authors instituted an active surveillance system to detect, categorize, and grade the severity of all adverse events after pancreatectomy, using the modified Accordion system and International Study Group of Pancreatic Surgery definitions. All patients and clinical events were monitored directly for at least 90 days after surgery. Results: Of 315 consecutively monitored patients, 239 (76 %) experienced 500 unique adverse events. The absolute number of unique adverse events increased by 32 % between index discharge and 90 days and by 10 % between 30 and 90 days. The number of severe adverse events increased by 96 % between discharge and 90 days and by 29 % between 30 and 90 days. In this study, 16 % of the patients experienced at least one severe adverse event within the index hospitalization, 24 % within 30 postoperative days, and 29 % within 90 days. Among the 80 readmissions that occurred within 90 days, 28 (35 %) occurred later than 30 days after pancreatectomy. Conclusions: Approximately one-third of severe adverse events and readmissions are reported more than 30 days after surgery. All adverse events that occur within 90 days of surgery must be identified and reported for accurate characterization of the morbidity associated with pancreatectomy.
AB - Background: The rate of adverse events after pancreatectomy is widely reported as a measure of surgical quality. However, morbidity data are routinely acquired retrospectively and often are reported at 30 days. The authors hypothesized that morbidity after pancreatectomy is therefore underreported. They sought to compare rates of adverse events calculated at multiple time points after pancreatectomy. Methods: The authors instituted an active surveillance system to detect, categorize, and grade the severity of all adverse events after pancreatectomy, using the modified Accordion system and International Study Group of Pancreatic Surgery definitions. All patients and clinical events were monitored directly for at least 90 days after surgery. Results: Of 315 consecutively monitored patients, 239 (76 %) experienced 500 unique adverse events. The absolute number of unique adverse events increased by 32 % between index discharge and 90 days and by 10 % between 30 and 90 days. The number of severe adverse events increased by 96 % between discharge and 90 days and by 29 % between 30 and 90 days. In this study, 16 % of the patients experienced at least one severe adverse event within the index hospitalization, 24 % within 30 postoperative days, and 29 % within 90 days. Among the 80 readmissions that occurred within 90 days, 28 (35 %) occurred later than 30 days after pancreatectomy. Conclusions: Approximately one-third of severe adverse events and readmissions are reported more than 30 days after surgery. All adverse events that occur within 90 days of surgery must be identified and reported for accurate characterization of the morbidity associated with pancreatectomy.
UR - http://www.scopus.com/inward/record.url?scp=84941418709&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941418709&partnerID=8YFLogxK
U2 - 10.1245/s10434-015-4437-z
DO - 10.1245/s10434-015-4437-z
M3 - Article
C2 - 25694246
AN - SCOPUS:84941418709
SN - 1068-9265
VL - 22
SP - 3522
EP - 3529
JO - Annals of surgical oncology
JF - Annals of surgical oncology
IS - 11
ER -